Decreasing Rx co-payments boost drug adherence by chronic disease patients

Article

Chronic disease patients are more compliant when Rx co-payments decrease.

Removing economic barriers to treatment for chronic conditions encourages patients to remain on recommended therapies, according to a new study published in the January/February 2008 issue of Health Affairs. The study, funded in part by GlaxoSmithKline, investigated the impact on medication adherence of reducing prescription co-payments—in addition to existing disease management programs—for employees of a leading service industry company. "The Impact of Decreasing Co-payments on Medication Adherence in the Context of a Disease Management Program" covered a 12-month study. Co-payment rates for generic medications were reduced from $5 to $0; co-payments for branded drugs were cut in half.

To see more Daily News articles, click here.

To go to the Drug Topics homepage, click here.

 

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.